An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms

StatusSuspended
PhaseNot specified
SponsorQbtech AB
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment suspended Sponsor's reason: Enrollment/study activities have been temporarily suspended while the sponsor evaluates internal study priorities and resource allocation. The suspension is not related to participant safety, protocol compliance, data quality, or regulatory concerns. Show 5 more changesShow less
    • Primary and study completion pushed from Nov 2026 to Nov 2027
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 10 of 10 entries
    • Study description revised
    • Site details revised
  2. Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2026 to Jan 1, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Qbtech AB
4 trials monitored
See all monitored trials
Anxiety
3,284 trials monitored
See 154 trials at risk
Depression
3,069 trials monitored
See 170 trials at risk
Bipolar Disorder
411 trials monitored
See 25 trials at risk
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
Trial Details
NCT Number NCT07329673
Lead Sponsor Qbtech AB
Conditions
(from sponsor)		 Bi-Polar Disorder, Autism Spectrum Disorder (ASD), Major Depression Disorders, Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Related terms Anxiety, Separation, Autism Spectrum Disorder, Bipolar Disorder, Generalized Anxiety Disorder, Phobia, Social
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov